Investors

NASDAQ: STEM

Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability.

Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company’s proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for chronic spinal cord injury (SCI). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product.

Driven by more than 20 years of pio...  More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
Letter to Investors
January 2015  Letter to Investors from CEO Martin McGlynn
Recent News
02/04/16Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference
NEWARK, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3rd Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Commun... 
Printer Friendly Version
01/28/16StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference
StemCells, Inc. Was Voted the 2016 Winner “Buzz of BIO” Public Company NEWARK, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make presentations on the Company's programs, pipeline and operations at two upcoming conferences in February. The Company will be presenting at the 2016 BIO CEO Conference on Feb. 8 at 2:30 p.m. Eastern Standard Time at the Waldorf Astoria in New York City. StemCells, Inc. was recognized as the most inno... 
Printer Friendly Version
01/11/16StemCells, Inc. CEO Martin McGlynn Passes Baton to President and COO Ian Massey
Experienced Biotech Leader to Become Next Chief Executive Officer NEWARK, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced that Dr. Ian Massey, its President and Chief Operating Officer, has been appointed by the Board of Directors to succeed Martin McGlynn as the Company’s Chief Executive Officer, effective January 18, 2016. ... 
Printer Friendly Version
01/06/16StemCells, Inc. to Participate at the 8th Annual Biotech Showcase Investor Conference
Management Will Present an Update on the Company’s Programs, Pipeline and Operations NEWARK, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 8th Annual Biotech Showcase Investor Conference.  Management is scheduled to speak at 4:30 p.m. Pacific Standard Time on Monday, January 11, at the Parc 55 Hotel, located at 55 Cyril Magnin Street, San Francisco. A... 
Printer Friendly Version
More >>
Upcoming Events
Webcast ImageWebcast
StemCells, Inc. at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference  (Live)
02/10/16 at 9:30 a.m. ET
DateTitle
02/10/16
StemCells, Inc. at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference
Presentations
DateTitle
01/11/16
Download Documentation StemCells, Inc. at the 8th Annual Biotech Showcase Investor Conference
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$0.31
Change (%) Stock is Down 0.01 (3.13%)
Volume205,116
Data as of 02/09/16 12:21 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet